These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7201207)

  • 21. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review).
    Boulikas T; Vougiouka M
    Oncol Rep; 2004 Mar; 11(3):559-95. PubMed ID: 14767508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New frontiers in cancer chemotherapy: cis-platinum].
    Sulkes A; Peretz T; Rizel S; Yahalom Y; Brian S
    Harefuah; 1986 Jan; 110(2):90-3. PubMed ID: 3516812
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinico-morphological comparisons of the results of the combined treatment of tumors with platinum derivatives].
    Shalimov SA; Keĭsevich LV; Nikishin LF; Trokhimenko EP; Evtushenko GV
    Vrach Delo; 1988 Jul; (7):79-82. PubMed ID: 3188478
    [No Abstract]   [Full Text] [Related]  

  • 25. Modern methods for diagnosis and monitoring of nephrotoxicity during antitumor therapy with platinum derivatives.
    Lyubimova NV; Topchieva SV; Averinova SG; Kashkadaeva AV; Gorbunova VA; Shiryaev SV; Kushlinskii NE
    Bull Exp Biol Med; 2000 Sep; 130(9):886-91. PubMed ID: 11177273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weekly administration of cis-dichlorodiammineplatinum(II) in childhood solid tumors: a Southwest Oncology Group study.
    Nitschke R; Fagundo R; Berry DH; Falletta JM
    Cancer Treat Rep; 1979 Mar; 63(3):497-9. PubMed ID: 427829
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of acquired cisplatin resistance on the response of a xenografted human hypopharynx carcinoma to concurrent radiochemotherapy with cisplatin.
    Jäckel M; Tausch-Treml R; Köpf-Maier P
    Laryngoscope; 1994 Mar; 104(3 Pt 1):329-34. PubMed ID: 8127191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The future role of carboplatin.
    Ruckdeschel JC
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):114-8. PubMed ID: 7992063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases.
    Hill JM; Loeb E; MacLellan A; Hill NO; Khan A; King JJ
    Cancer Chemother Rep; 1975; 59(3):647-59. PubMed ID: 1203889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granisetron in repeated cycles of chemotherapy with platinum.
    Tzekova VI; Velikova MT; Koynov KD
    Neoplasma; 1998; 45(1):46-9. PubMed ID: 9605002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 1997 Jun; 65(3):434-6. PubMed ID: 9190971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platinum chemotherapy during pregnancy for serous cystadenocarcinoma of the ovary.
    Henderson CE; Elia G; Garfinkel D; Poirier MC; Shamkhani H; Runowicz CD
    Gynecol Oncol; 1993 Apr; 49(1):92-4. PubMed ID: 8482567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma.
    Belani CP
    Semin Oncol; 2004 Dec; 31(6 Suppl 14):25-33. PubMed ID: 15726531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer].
    Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H
    Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Focus: platinum in chemotherapy].
    Pimentel I; Dicato M
    Bull Soc Sci Med Grand Duche Luxemb; 1980; 117(1):41-3. PubMed ID: 7194746
    [No Abstract]   [Full Text] [Related]  

  • 37. [Results of a clinical study of cis-diamminodichloroplatinum].
    Gorbunova VA; Moroz LV
    Vestn Akad Med Nauk SSSR; 1981; (7):72-6. PubMed ID: 7197436
    [No Abstract]   [Full Text] [Related]  

  • 38. Nursing implications of cis-platinum therapy.
    Higgins NM
    Oncol Nurs Forum; 1978; 5(1-2):3-4. PubMed ID: 247480
    [No Abstract]   [Full Text] [Related]  

  • 39. [Cis-diamminedichloroplatinum(II): a new type of cytostatic].
    Sonntag RW
    Onkologie; 1979 Jun; 2(3):129-33. PubMed ID: 118414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trace element analysis in body fluids by glow discharge mass spectrometry: a study of lead mobilization by the drug cis-platin.
    Evetts I; Milton D; Mason R
    Biol Mass Spectrom; 1991 Mar; 20(3):153-9. PubMed ID: 2069985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.